1
|
Interleukin-6 signaling pathway in targeted therapy for cancer.
|
Cancer Treat Rev
|
2012
|
2.82
|
2
|
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
|
Cancer
|
2014
|
1.43
|
3
|
MicroRNA Involvement in Osteosarcoma.
|
Sarcoma
|
2012
|
1.38
|
4
|
Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.
|
Cancer Res
|
2007
|
1.34
|
5
|
Recurrent chromosomal copy number alterations in sporadic chordomas.
|
PLoS One
|
2011
|
1.24
|
6
|
Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.
|
PLoS One
|
2010
|
1.16
|
7
|
Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
|
Cancer Res
|
2003
|
1.15
|
8
|
High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
|
Cancer
|
2011
|
1.13
|
9
|
Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.
|
Clin Cancer Res
|
2008
|
1.12
|
10
|
Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
|
Am J Surg Pathol
|
2013
|
1.08
|
11
|
A novel target for treatment of chordoma: signal transducers and activators of transcription 3.
|
Mol Cancer Ther
|
2009
|
1.07
|
12
|
Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
|
Mol Pharm
|
2010
|
1.07
|
13
|
Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
|
Clin Cancer Res
|
2010
|
1.06
|
14
|
Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.
|
BMC Cancer
|
2009
|
1.05
|
15
|
ROCK1 as a potential therapeutic target in osteosarcoma.
|
J Orthop Res
|
2011
|
1.04
|
16
|
Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.
|
Int J Cancer
|
2007
|
1.04
|
17
|
Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis.
|
J Orthop Res
|
2010
|
1.03
|
18
|
Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning.
|
Cancer Cell Int
|
2011
|
1.02
|
19
|
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.
|
Cancer Chemother Pharmacol
|
2010
|
1.01
|
20
|
The kinase Mirk is a potential therapeutic target in osteosarcoma.
|
Carcinogenesis
|
2009
|
1.01
|
21
|
Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
|
BMC Cancer
|
2010
|
1.00
|
22
|
Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
|
PLoS One
|
2011
|
1.00
|
23
|
Characterization and analysis of human chordoma cell lines.
|
Spine (Phila Pa 1976)
|
2010
|
0.97
|
24
|
Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.
|
Anticancer Res
|
2009
|
0.97
|
25
|
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
|
Int J Cancer
|
2008
|
0.95
|
26
|
Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.
|
PLoS One
|
2013
|
0.95
|
27
|
Targeting hedgehog-GLI-2 pathway in osteosarcoma.
|
J Orthop Res
|
2012
|
0.92
|
28
|
MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug.
|
J Orthop Res
|
2014
|
0.92
|
29
|
Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems.
|
AAPS J
|
2010
|
0.91
|
30
|
Establishment and characterization of a novel chordoma cell line: CH22.
|
J Orthop Res
|
2012
|
0.89
|
31
|
Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.
|
Cancer Lett
|
2013
|
0.89
|
32
|
Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.
|
Anticancer Res
|
2011
|
0.88
|
33
|
Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.
|
Mol Pharm
|
2008
|
0.88
|
34
|
Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
|
Pharm Res
|
2014
|
0.88
|
35
|
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
|
Anticancer Drugs
|
2011
|
0.87
|
36
|
Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking.
|
Mol Cancer Ther
|
2010
|
0.87
|
37
|
Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.
|
J Orthop Res
|
2014
|
0.86
|
38
|
Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients.
|
Virchows Arch
|
2007
|
0.86
|
39
|
beta tubulin mutations are rare in human ovarian carcinoma.
|
Anticancer Res
|
2003
|
0.86
|
40
|
Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.
|
Clin Orthop Relat Res
|
2013
|
0.85
|
41
|
Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression.
|
Apoptosis
|
2009
|
0.85
|
42
|
BRAF mutation in 'sarcomas': a possible method to detect de-differentiated melanomas.
|
Histopathology
|
2013
|
0.83
|
43
|
RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
|
Cancer Chemother Pharmacol
|
2009
|
0.82
|
44
|
Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma.
|
Spine (Phila Pa 1976)
|
2010
|
0.82
|
45
|
Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
|
J Biomol Screen
|
2010
|
0.82
|
46
|
Guanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistance.
|
Cancer Sci
|
2014
|
0.81
|
47
|
Proteomic profiling of chordoma.
|
J Surg Oncol
|
2010
|
0.80
|
48
|
Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors.
|
Mol Pharm
|
2014
|
0.78
|
49
|
Nanoparticles: a promising modality in the treatment of sarcomas.
|
Pharm Res
|
2010
|
0.78
|
50
|
Decreased expression and activation of Stat3 in severe preeclampsia.
|
J Mol Histol
|
2015
|
0.77
|
51
|
Development of a new pre-vascularized tissue-engineered construct using pre-differentiated rADSCs, arteriovenous vascular bundle and porous nano-hydroxyapatide-polyamide 66 scaffold.
|
BMC Musculoskelet Disord
|
2013
|
0.75
|
52
|
Microbubble embedded with upconversion nanoparticles as a bimodal contrast agent for fluorescence and ultrasound imaging.
|
Nanotechnology
|
2015
|
0.75
|
53
|
Inkjet printing of upconversion nanoparticles for anti-counterfeit applications.
|
Nanoscale
|
2015
|
0.75
|
54
|
Facial Layer-by-Layer Engineering of Upconversion Nanoparticles for Gene Delivery: Near-Infrared-Initiated Fluorescence Resonance Energy Transfer Tracking and Overcoming Drug Resistance in Ovarian Cancer.
|
ACS Appl Mater Interfaces
|
2017
|
0.75
|
55
|
Three-dimensional (3D) culture in sarcoma research and the clinical significance.
|
Biofabrication
|
2017
|
0.75
|
56
|
[Regulation of chondrosarcoma cell growth using synthesized hydrogels with different electric charges].
|
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
|
2013
|
0.75
|
57
|
Multiscale agent-based modelling of ovarian cancer progression under the stimulation of the STAT 3 pathway.
|
Int J Data Min Bioinform
|
2014
|
0.75
|